Jane Whitrow

Jane Whitrow has a diverse work experience spanning over several years. In their most recent role, they served as the Interim Chief Operations Officer at Adrestia Therapeutics from April 2021 to the present. Prior to that, they worked as a Finance & Business Consultant at JLJ Scientific Services and Mestag Therapeutics from April 2020 onward.

From October 2018 to April 2020, Jane held the position of VP Business Operations at Freeline Therapeutics Limited, where they were responsible for overseeing business operations. Jane also served as the VP of Finance at the same company from October 2016 to April 2020.

Before joining Freeline Therapeutics, Jane worked at IXICO plc as the VP of Business Operations from September 2009 to September 2016. During their time there, they played a significant role in the reverse takeover of Phytopharm plc and AIM listing in October 2013.

Jane also worked part-time as the VP of Corporate Affairs at Novacta Biosystems Limited from October 2009 to November 2011. Prior to this, they worked as the Finance Director at Cambridge Biostability Limited from April 2005 to June 2009.

Jane started their career as a Finance Professional at Self-Employed (Special Projects) from August 2003 to March 2005. Jane then joined Merlin Biosciences as the Finance Director in October 1997, where they had the opportunity to work with various biotech start-up companies.

Jane began their professional journey as an Auditor at KPMG, where they gained experience across a wide range of businesses. Jane was with KPMG from September 1992 to October 1997.

Jane Whitrow earned a BSc (hons) in Plant and Animal Biology from The University of Manchester from 1984 to 1987. Jane then pursued further education at the University of Birmingham, where they obtained a PhD in Genetics from 1987 to 1990.